The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
Hiroshi Okabe
No relevant relationships to disclose
Hiroaki Hata
No relevant relationships to disclose
Shugo Ueda
No relevant relationships to disclose
Masazumi Zaima
No relevant relationships to disclose
Atsuo Tokuka
No relevant relationships to disclose
Tsunehiro Yoshimura
No relevant relationships to disclose
Shuichi Ota
No relevant relationships to disclose
Yousuke Kinjo
No relevant relationships to disclose
Kenichi Yoshimura
No relevant relationships to disclose
Yoshiharu Sakai
No relevant relationships to disclose